KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Other (2017 - 2026)

Amneal Pharmaceuticals has reported Receivables - Other over the past 9 years, most recently at $24.2 million for Q4 2025.

  • For Q4 2025, Receivables - Other rose 1195.5% year-over-year to $24.2 million; the TTM value through Dec 2025 reached $24.2 million, up 1195.5%, while the annual FY2025 figure was $24.2 million, 1195.5% up from the prior year.
  • Receivables - Other for Q4 2025 was $24.2 million at Amneal Pharmaceuticals, up from $14.8 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $47.2 million in Q1 2022 and troughed at $1.1 million in Q1 2021.
  • A 5-year average of $10.9 million and a median of $5.1 million in 2023 define the central range for Receivables - Other.
  • Biggest five-year swings in Receivables - Other: surged 4184.3% in 2022 and later tumbled 93.36% in 2023.
  • Year by year, Receivables - Other stood at $1.2 million in 2021, then skyrocketed by 2710.26% to $33.1 million in 2022, then tumbled by 93.36% to $2.2 million in 2023, then decreased by 15.09% to $1.9 million in 2024, then soared by 1195.5% to $24.2 million in 2025.
  • Business Quant data shows Receivables - Other for AMRX at $24.2 million in Q4 2025, $14.8 million in Q3 2025, and $3.7 million in Q2 2025.